以皮疹为首发表现的高龄IgG4相关性疾病1例

[1]	FLOREANI A, OKAZAKI K, UCHIDA K, et al. IgG4-related disease: Changing epidemiology and new thoughts on a multisystem disease[J]. J Transl Autoimmun, 2020, 4: 100074. DOI: 10.1016/j.jtauto.2020.100074.
[2]	OBIORAH I E, HENAO V A, OZDEMIRLI M. The clinicopathologic spectrum of IgG4-related disease[J]. Balkan Med J, 2018, 35(4): 292-300. doi: 10.4274/balkanmedj.2018.0809
[3]	BENNETT A E, FENSKE N A, RODRIGUEZ-WAITKUS P, et al. IgG4-related skin disease may have distinct systemic manifestations: A systematic review[J]. Int J Dermatol, 2016, 55(11): 1184-1195. doi: 10.1111/ijd.13369
[4]	张文, 董凌莉, 朱剑, 等. IgG-4相关性疾病诊治中国专家共识[J]. 中华内科杂志, 2021, 60(3): 192-206. https://www.cnki.com.cn/Article/CJFDTOTAL-LCGD202109013.htm ZHANG W, DONG L L, ZHU J, et al. Chinese expert consensus on the diagnosis and treatment of IgG4-related diseases[J]. Chinese Journal of Internal Medicine, 2021, 60(3): 192-206. https://www.cnki.com.cn/Article/CJFDTOTAL-LCGD202109013.htm
[5]	WALLACE Z S, PERUGINO C, MATZA M, et al. Immunoglobulin G4-related disease[J]. Clin Chest Med, 2019, 40(3): 583-597. doi: 10.1016/j.ccm.2019.05.005
[6]	TAKAYAMA R, UENO T, SAEKI H. Immunoglobulin G4-related disease and its skin manifestations[J]. J Dermatol, 2017, 44(3): 288-296. doi: 10.1111/1346-8138.13723
[7]	SHENOY A, MOHANDAS N, GOTTLIEB A. Cutaneous and systemic IgG4-related disease: A review for dermatologists[J]. Dermatol Online J, 2019, 25(6): 13030. DOI: 10.5070/D3256044441.
[8]	ISHIMOTO U, KINOSHITA A, KOIKE K, et al. Punctate purpura complicated with Immunoglobulin G4-related disease[J]. Intern Med, 2021, 60(6): 867-872. doi: 10.2169/internalmedicine.5138-20
[9]	刘佳玮, 刘薇, 马东来. IgG4相关性疾病的皮肤表现[J]. 临床皮肤科杂志, 2017, 46(10): 733-735. https://www.cnki.com.cn/Article/CJFDTOTAL-LCPF201710019.htm LIU J W, LIU W, MA D L. Skin manifestation of IgG4-related disease[J]. Journal of Clinical Dermatology, 2017, 46(10): 733-735. https://www.cnki.com.cn/Article/CJFDTOTAL-LCPF201710019.htm
[10]	WALLACE Z S, NADEN R P, CHARI S, et al. The 2019 American college of Rheumatology/European League against rheumatism classification criteria for IgG4-related disease[J]. Arthritis Rheumatol, 2020, 72(1): 7-19. doi: 10.1002/art.41120
[11]	WANG K K, WANG Z F, ZENG Q Z, et al. Clinical characteristics of IgG4-related retroperitoneal fibrosis versus idiopathic retroperitoneal fibrosis[J]. PLoS One, 2021, 16(2): e245601. DOI: 10.1371/journal.pone.0245601.
[12]	TANG J G, CAI S Z, YE C, et al. Biomarkers in IgG4-related disease: A systematic review[J]. Semin Arthritis Rheum, 2020, 50(2): 354-359. doi: 10.1016/j.semarthrit.2019.06.018
[13]	HARA A, WATANABE T, MINAGA K, et al. Biomarkers in autoimmune pancreatitis and immunoglobulin G4-related disease[J]. World J Gastroenterol, 2021, 27(19): 2257-2269. doi: 10.3748/wjg.v27.i19.2257
[14]	MATSUMOTO H, FUJITA Y, MATSUOKA N, et al. Serum checkpoint molecules in patients with IgG4-related disease (IgG4-RD)[J]. Arthritis Res Ther, 2021, 23(1): 148. doi: 10.1186/s13075-021-02527-6
[15]	ZHANG P P, GONG Y Y, LIU Z, et al. Efficacy and safety of iguratimod plus corticosteroid as bridge therapy in treating mild IgG4-related diseases: A prospective clinical trial[J]. Int J Rheum Dis, 2019, 22(8): 1479-1488. doi: 10.1111/1756-185X.13633